RTW Biotech Opportunities (RTW) has reported strong full-year results for the year ended 31 December 2024. Its NAV rose from US$399m to US$607m, marking a year of substantial portfolio growth, positive clinical milestones, and a number of key capital markets events. Despite a -4.6% NAV per share movement over the year (due to share issuance … Continue reading RTW Biotech Opportunities reports strong 2024 and outlines bullish 2025 outlook